18 August 2022 | News
Vijender Singh was the CEO of Metropolis Healthcare and COO of Dr Lal’s Pathlabs while Matai was the MD of Zydus Healthcare and CEO of Novartis Pharma India
(L-R) Vijender Singh and Anil Matai
India-focused growth private equity firm Jashvik Capital announced the appointment of Anil Matai and Vijender Singh as operating partners.
Vijender Singh was most recently CEO of Metropolis Healthcare and COO of Dr Lal Pathlabs. Singh helped scale both these companies under private equity ownership. Previously, he held leadership roles at Ranbaxy Labs, in their OTC/Wellness business, and at Bausch & Lomb.
Matai was most recently the Managing Director of Zydus Healthcare and CEO of Novartis Pharma India. Under his leadership, Zydus made significant strides in delivering affordable care and gained significant market share while improving margins. Previously, he also held leadership positions at GlaxoSmithKline India.